SCHEMBL7949968

SCHEMBL7949968

Cc1ccc(S(=O)(=O)OCC2(COS(=O)(=O)c3ccc(C)cc3)CCC(O)CC2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.41
STAT3 P40763 2/20 0.39
CYP1A2 P05177 1/20 0.39
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALDH1A1 P00352 2/20 0.37
TP53 P04637 1/20 0.37
POLB P06746 1/20 0.37
ENPP3 O14638 2/20 0.37
ENPP1 P22413 2/20 0.37
ENPP2 Q13822 2/20 0.37
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
PKM P14618 1/20 0.35
CYP2C19 P33261 1/20 0.35
CRBN Q96SW2 1/20 0.35
GAA P10253 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
SIRT5 Q9NXA8 1/20 0.35
ACHE P22303 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12246564 0.93 ALDH1A1 (0.40) CYP2D6STAT3CYP1A2KMT2ASMN1; SMN2
SCHEMBL18047923 0.86 SMN1; SMN2 (0.46) CYP2D6STAT3CYP1A2KMT2ASMN1; SMN2
SCHEMBL11637311 0.83 KMT2A (0.47) CYP2D6STAT3CYP1A2KMT2ASMN1; SMN2
SCHEMBL7849587 0.81 KMT2A (0.50) STAT3KMT2ASMN1; SMN2ALDH1A1TP53
SCHEMBL18334492 0.79 KMT2A (0.41) CYP2D6STAT3KMT2ASMN1; SMN2ALDH1A1
SCHEMBL1821908 0.79 ALDH1A1 (0.43) KMT2ASMN1; SMN2ALDH1A1TP53POLB
SCHEMBL3304120 0.79 CYP3A4 (0.49) STAT3KMT2ASMN1; SMN2ALDH1A1CYP3A4
SCHEMBL9942928 0.79 KMT2A (0.40) CYP2D6STAT3CYP1A2KMT2ASMN1; SMN2
SCHEMBL30140023 0.78 KMT2A (0.42) CYP2D6STAT3KMT2ASMN1; SMN2ALDH1A1
SCHEMBL16035308 0.78 KMT2A (0.39) CYP2D6STAT3CYP1A2KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4562014-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME Cedilla Therapeutics, Inc. (US) 2025-06-04 EP disclosed
WO-2024026479-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 WO disclosed
EP-3911641-A1 NLRP3 MODULATORS Innate Tumor Immunity, Inc. (US) 2021-11-24 EP disclosed
WO-2020150115-A1 NLRP3 MODULATORS INNATE TUMOR IMMUNITY, INC. (US) 2020-07-23 WO disclosed
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
EP-2324032-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2014-10-01 EP disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
WO-2010021680-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218192-A1 Inhibitors Of Beta-Secretase BACE1, BACE2, APP CYP2D6 3062/4885STAT3 4488/4885CYP1A2 2797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.